BEAM pipeline advances: pivotal trials progress in AATD and sickle cell
BEAM says pivotal trials are advancing for AATD and sickle cell, citing strong clinical data and regulatory alignment aimed at accelerated approval. The platform supports expansion into new indications and commercialization targeting diagnosed and undiagnosed patients.